Literature DB >> 31419537

Gene expression associated with immune response in Atlantic salmon head-kidney vaccinated with inactivated whole-cell bacterin of Piscirickettsia salmonis and pathogenic isolates.

Marco Rozas-Serri1, Andrea Peña2, Lucerina Maldonado2.   

Abstract

Piscirickettsiosis is the most challenging disease present in the Chilean salmon industry. The aim of this study was to describe the expression of genes associated with immune response of Atlantic salmon intraperitoneally infected with LF-89 and EM-90 Piscirickettsia salmonis and vaccinated with inactivated whole-cell bacterin of P. salmonis. The fish infected with PS-LF-89 showed an anti-inflammatory response, whereas this finding was not observed in the PS-EM-90-infected fish and vaccinated fish. Fish infected with both P. salmonis isolates showed mhc1-mhc2, cd4-cd8b and igm overexpression, suggesting that P. salmonis promotes a T CD4+ and T CD8+ cell response and a humoral immune response. The vaccinated-fish exhibited mhc1, mhc2 and cd4 overexpression but a significant downregulation of cd8b and igm, suggesting that the vaccine supported the CD4+ T-cell response but did not induce an immune response mediated by CD8+ T cells or a humoral response. In conclusion, the expression pattern of genes related to the humoral and cell-mediated adaptive immune response showed upregulation in fish infected with P. salmonis and down-regulation in vaccinated fish. The results of this study contribute to our understanding of the immune response against P. salmonis and can be used in the optimization of SRS prevention and control measures.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Immune response; Piscirickettsia salmonis; Piscirickettsiosis; Vaccination

Mesh:

Substances:

Year:  2019        PMID: 31419537     DOI: 10.1016/j.fsi.2019.08.031

Source DB:  PubMed          Journal:  Fish Shellfish Immunol        ISSN: 1050-4648            Impact factor:   4.581


  6 in total

1.  Protein-Based Vaccine Protect Against Piscirickettsia salmonis in Atlantic Salmon (Salmo salar).

Authors:  Juan Pablo Pontigo; Carla Espinoza; Mauricio Hernandez; Guillermo Nourdin; Cristian Oliver; Rubén Avendaño-Herrera; Jaime Figueroa; Cecilia Rauch; José M Troncoso; Luis Vargas-Chacoff; Alejandro J Yáñez
Journal:  Front Immunol       Date:  2021-02-17       Impact factor: 7.561

2.  Chimeric Protein IPath® with Chelating Activity Improves Atlantic Salmon's Immunity against Infectious Diseases.

Authors:  Valentina Valenzuela-Muñoz; Bárbara P Benavente; Antonio Casuso; Yeny Leal; Cristian Gallardo-Escárate
Journal:  Vaccines (Basel)       Date:  2021-04-09

Review 3.  Why Does Piscirickettsia salmonis Break the Immunological Paradigm in Farmed Salmon? Biological Context to Understand the Relative Control of Piscirickettsiosis.

Authors:  Marco Rozas-Serri
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

4.  Commercial Vaccines Do Not Confer Protection against Two Genogroups of Piscirickettsia salmonis, LF-89 and EM-90, in Atlantic Salmon.

Authors:  Carolina Figueroa; Débora Torrealba; Byron Morales-Lange; Luis Mercado; Brian Dixon; Pablo Conejeros; Gabriela Silva; Carlos Soto; José A Gallardo
Journal:  Biology (Basel)       Date:  2022-06-30

5.  Atlantic Salmon Pre-smolt Survivors of Renibacterium salmoninarum Infection Show Inhibited Cell-Mediated Adaptive Immune Response and a Higher Risk of Death During the Late Stage of Infection at Lower Water Temperatures.

Authors:  Marco Rozas-Serri; Carlos Lobos; Rodolfo Correa; Ricardo Ildefonso; Jorge Vásquez; Ariel Muñoz; Lucerina Maldonado; Victoria Jaramillo; Darling Coñuecar; Camila Oyarzún; Romina Walker; Carolina Navarrete; Jorge Gayosa; Patricio Mancilla; Andrea Peña; Carolina Senn; Francisco Schwerter
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

6.  Host genetic variation explains reduced protection of commercial vaccines against Piscirickettsia salmonis in Atlantic salmon.

Authors:  Carolina Figueroa; Pamela Veloso; Lenin Espin; Brian Dixon; Débora Torrealba; Islam Said Elalfy; Juan Manuel Afonso; Carlos Soto; Pablo Conejeros; José A Gallardo
Journal:  Sci Rep       Date:  2020-10-26       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.